Rate Control in Decompensated Heart Failure

Introduction to Rate Control Agents

• Beta-blockers and amiodarone are the preferred rate control agents for patients with decompensated heart failure in whom nondihydropyridine calcium channel antagonists are contraindicated, as recommended by the American Heart Association and American College of Cardiology 1, 2
• Nondihydropyridine calcium channel blockers should not be used in patients with decompensated heart failure due to their potential for further hemodynamic compromise, with a Class III: Harm recommendation from the American Heart Association, American College of Cardiology, and Heart Rhythm Society 1, 2

Preferred Rate Control Agents

• Intravenous beta-blockers are preferred in hemodynamically stable patients with decompensated heart failure, according to the American College of Cardiology 1
• Beta-1 selective agents, such as metoprolol, are preferred over non-selective agents in patients with heart failure, as recommended by the American College of Cardiology 3
• Amiodarone is a Class IIa recommendation for rate control in critically ill patients with decompensated heart failure, as per the American College of Cardiology and American Heart Association 1, 2

Alternative Rate Control Agents

• Digoxin may be considered as an adjunct for rate control in heart failure patients who have an insufficient response to beta-blockers, as recommended by the European Society of Cardiology 4
• Digoxin is particularly useful in patients with reduced ejection fraction, according to the American Heart Association 5

Interventional Procedures

• Electrical cardioversion is indicated for hemodynamically unstable patients with decompensated heart failure, as recommended by the European Society of Cardiology 4
• AV nodal ablation with permanent pacing is a reasonable option when pharmacological therapy is inadequate in patients with decompensated heart failure, as recommended by the American College of Cardiology and American Heart Association 1, 2

Assessment and Management

• Hemodynamic stability should be assessed in patients with decompensated heart failure, and immediate electrical cardioversion should be performed if the patient is unstable, as recommended by the European Society of Cardiology 4
• For pharmacological rate control, intravenous beta-blockers are the first choice, unless the patient is severely decompensated, in which case intravenous amiodarone may be considered, according to the American College of Cardiology 1, 2

Monitoring and Safety

• Beta-blockers should be initiated cautiously in patients with heart failure who have reduced ejection fraction, as recommended by the American College of Cardiology 3
• Hypotension should be monitored for when initiating rate control agents in patients with decompensated heart failure, according to the American College of Cardiology 1
• Diltiazem should be avoided in patients with congestive heart failure (CHF), particularly those with reduced ejection fraction, due to its negative inotropic effects, as recommended by the European Society of Cardiology 6, 7
• The combination of verapamil or diltiazem with beta-blockers is harmful in heart failure patients with atrial fibrillation (Class III recommendation), according to the American College of Cardiology and American Heart Association 8